KAI Pharmaceuticals and Sankyo entered into agreement to develop KAI-9803 which is in phase 1/2 clinical trials for treating myocardial tissue death and associated congestive heart failure in acute myocardial infarction. The deal could be worth up to US$340 M to KAI.